Related Experiment Video
Updated: Jan 30, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy
Anne M Connolly1,2, Craig M Zaidman1,2, Paul T Golumbek1,2
1Department of Neurology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, 63110, USA.
Insights
Twice-weekly glucocorticosteroids (GC) in young boys with Duchenne muscular dystrophy (DMD) improved gross motor function. While generally well-tolerated, excessive weight gain was noted, requiring further investigation for long-term feasibility.
Area of Science:
- Pediatric Neurology
- Genetics and Genetic Diseases
- Clinical Trials
Background:
- Glucocorticosteroids (GC) are established treatments for slowing muscle weakness in Duchenne muscular dystrophy (DMD).
- Early intervention in DMD is crucial for optimizing long-term outcomes.
- The safety and efficacy of GC in very young DMD patients require further evaluation.
Purpose of the Study:
- To assess the efficacy and tolerability of twice-weekly prednisolone in infants and young boys with DMD.
- To compare motor development outcomes in treated infants/boys with a historical control cohort.
Main Methods:
- A 1-year, open-label, multisite trial involving 25 infants/young boys (0.4-2.4 years) with DMD receiving twice-weekly prednisolone.
- Motor development was assessed using the Bayley III Scales of Infant Development (Bayley-III), specifically the Gross Motor Scaled Score (GMSS).
- Outcomes were compared to a historical control cohort (HCC) of untreated boys.
Main Results:
- Treated boys showed an average gain of 0.5 points in GMSS, while the HCC declined by 1.3 points (P=0.03).
- All participants maintained linear growth, and no Cushingoid features were observed.
- Excessive weight gain occurred in 56% of treated boys.
Conclusions:
- Twice-weekly GC administration appears well-tolerated in infants and young boys with DMD and demonstrates a positive impact on gross motor function.
- Excessive weight gain is a notable side effect that warrants monitoring.
- Further long-term studies are needed to confirm the feasibility of early GC initiation in this population.
Introduction:
Glucocorticosteroids (GC) are effective in slowing weakness in boys with Duchenne muscular dystrophy (DMD).
Methods:
This is a multisite, 1-year, open-label trial of twice-weekly prednisolone (5 mg/kg/dose) in infants/young boys (0.4-2.4 years) with DMD. We compared changes in Bayley III Scales of Infant Development (Bayley-III) with untreated boys followed for 1 year (historical control cohort [HCC]). Twenty-three of 25 participants completed the study.
Results:
Treated boys gained an average of 0.5 points on the Bayley-III gross motor scaled score (GMSS) compared with the HCC who, on average, declined 1.3 points (P = 0.03). All boys maintained linear growth, and none developed Cushingoid features. Excessive weight gain occurred in 13 of 23 (56%) boys.
Discussion:
This study provides evidence that twice-weekly GC is well tolerated in infants and young boys with DMD and improves GMSS. Excessive weight gain is a potential risk. Longer follow-up is required to determine whether early GC initiation is feasible in most infants/boys with DMD. Muscle Nerve 59:650-657, 2019.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
The Muscular System
Drug Dosing: Infants and Children
Robbers Cave
Bullying
Theory of Romantic Attachment in Adulthood

